Oncothyreon: Clinical Trial Update (Oncothyreon) - Jul 18, 2015 - “ONT-10 has been well tolerated at doses through 2000 μg administered weekly over an 8-week period and when administered once every 6 weeks for up to two years”; “Consistent with preclinical data, ONT-10 induces IgM and IgG anti-MUC1 response in the majority of patients, with titers frequently exceeding 1:50,000”; “IgG response dose and schedule dependent, with greatest response seen at 1000–2000 μg QW”; “Encouraging disease control in patients with heavily pretreated and incurable cancers, with > 70% of patients without progression by irRC at Week 12, and 11 patients to date without progression for > 6 months”
P1 data • Oncology
|